RxDoctor Payments Data

Amy Li, MD

Urology · Silverdale, WANPI 1275823684

Payments from drug & device makers

$2,440in general payments, 2019–2025

Across 64 payments — averaging $38.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$908
  • Myriad Genetic Laboratories, Inc.$256
  • Procept Biorobotics Corporation$241
  • Axonics, Inc.$171
  • Boston Scientific$140
  • Progenics Pharmaceuticals, Inc.$117
  • plus $607 from 16 others

What the payments were for

  • Travel & lodging$58024%
  • Food & beverage$1,84175%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,440 in reported general payments places this provider in the 55th percentile of 274 urology providers in Washington.

See all urology providers in Washington

Medicare billing

Part B allowed, 2024
$442,993
Medicare patients
737
Services billed
10,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron109$111,580
GemtesaVibegron43$44,827
Estradiol242$16,673
Tamsulosin Hcl214$3,586
Finasteride124$1,776
Potassium Citrate ErPotassium Citrate14$1,634
Trospium Chloride30$1,037
Methenamine Hippurate11$957
Alfuzosin Hcl ErAlfuzosin Hcl32$822
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$791
Cephalexin87$691
Oxybutynin Chloride ErOxybutynin Chloride16$469
Indapamide16$445
Dutasteride11$197
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen51$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$40$111,580109 claims
Sumitomo Pharma America, Inc.Gemtesa$23$44,82743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 274 urology providers in Washington.

Other urology in Silverdale

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →